NSPR Overview

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Wall Street analysts forecast NSPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NSPR is5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

InspireMD Inc revenue for the last quarter amounts to 3.15M USD, increased 61.57

InspireMD Inc. EPS for the last quarter amounts to -0.14 USD, decreased -26.32

InspireMD Inc (NSPR) has 127 emplpoyees as of March 31 2026.

Today NSPR has the market capitalization of 74.41M USD.